RVPH
Reviva Pharmaceuticals Holdings, Inc.Company with tickers: RVPH
CIK
1742927
CUSIP
76152G100
Shares Outstanding
13,110,377
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $6,538,167 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $4,113,537 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-6,538,167 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-6,432,840 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-2.61 | USD/shares | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | — |